"By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells. Doctors might someday use the approach to treat a variety of mito"...
Omnipred Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Omnipred (prednisolone acetate) Ophthalmic Suspension is an adrenocortical steroid is used to treat inflammation caused by allergies, eye infections, or any general irritation to the eye. Common side effects of Omnipred include increased pressure in the eyes, glaucoma, optic nerve damage, cataracts, and delayed wound healing.
The recommended dosage of Omnipred is two drops in the eyes four times per day. Other drugs may interact with Omnipred. Tell your doctor all medications you take. Do not stop using Omnipred suddenly. Avoid touching the bottle tip to eyelids or to any other surface. Use of the bottle by more than one person may spread the infection. If you are pregnant only use Omnipred if the potential benefit outweighs the potential risk to the fetus. Do not use Omnipred if you are breastfeeding.
Our Omnipred (prednisolone acetate) Ophthalmic Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Omnipred in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:
- pain behind your eyes, sudden vision changes, severe headache;
- sudden eye irritation;
- blurred vision, tunnel vision, eye pain, or seeing halos around lights; or
- signs of new eye infection, such as swelling, draining, or crusting of your eyes.
Less serious side effects may include:
- temporary cloudy vision;
- increased sensitivity to light; or
- mild stinging, burning, itching, or irritation in your eyes.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Omnipred (Prednisolone Acetate) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Omnipred FDA Prescribing Information: Side Effects
Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.
Corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids.
The development of secondary ocular infection (bacterial, fungal and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (SEE WARNINGS).
Read the entire FDA prescribing information for Omnipred (Prednisolone Acetate) »
Additional Omnipred Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.